Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies

Fred R. Hirsch, Keith M. Kerr, Paul A. Bunn, Edward S. Kim, Coleman Obasaju, Maurice Pérol, Philip Bonomi, Jeffrey D. Bradley, David Gandara, James R. Jett, Corey J. Langer, Ronald B. Natale, Silvia Novello, Luis Paz-Ares, Suresh S. Ramalingam, Martin Reck, Craig H. Reynolds, Egbert F. Smit, Mark A. Socinski, David R. SpigelThomas E. Stinchcombe, Johan F. Vansteenkiste, Heather Wakelee, Nick Thatcher

    Research output: Contribution to journalReview articlepeer-review

    13 Scopus citations

    Abstract

    Patients with non–small-cell lung cancer, including squamous-cell lung cancer (SqCLC), typically present at an advanced stage. The current treatment landscape, which includes chemotherapy, radiotherapy, surgery, immunotherapy, and targeted agents, is rapidly evolving, including for patients with SqCLC. Prompt molecular and immune biomarker testing can serve to guide optimal treatment choices, and immune biomarker testing is becoming more important for this patient population. In this review we provide an overview of current and emerging practices and technologies for molecular and immune biomarker testing in advanced non–small-cell lung cancer, with a focus on SqCLC.

    Original languageEnglish
    Pages (from-to)331-339
    Number of pages9
    JournalClinical Lung Cancer
    Volume19
    Issue number4
    DOIs
    StatePublished - Jul 2018

    Keywords

    • Immune-oncology
    • Molecular testing
    • Non–small-cell lung cancer
    • PD-L1
    • Pathology
    • Targeted treatment

    Fingerprint

    Dive into the research topics of 'Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies'. Together they form a unique fingerprint.

    Cite this